DARA is a pharmaceutical development company that acquires promising therapeutic molecules in early stage development. It then expedites development through proof-of-concept in humans for subsequent partnering, sale or out-licensing to large healthcare and pharmaceutical companies. The effective implementation of this strategy has the potential to greatly reduce costs and event risks in the development process.
To effectively manage the risks and returns of the Company, DARA utilizes a stringent due diligence process anchored by our knowledge of a drug or technology candidate’s attributes that will most likely yield commercial success. The due diligence, development and commercial expertise resident at DARA help ensure that we identify the highest caliber candidates. Precise, targeted research is then conducted to form a solid basis for future marketing approval as well as medical and commercial success.